-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the pharmaceutical equipment industry, the technical level of pharmaceutical equipment directly determines the future market share, and the performance of pharmaceutical equipment can reflect the company's business overview
.
So, in 2021, how about the performance of listed pharmaceutical equipment companies? At present, the listed companies in the domestic pharmaceutical equipment industry mainly include Xinhua Medical, Tofflon, Chutian Technology, Huasheng, Tailin Bio, Canaan Technology, etc.
Let's take a look at their performance
.
Pharmaceutical equipment (picture source: Pharmaceutical Network) The performance of pharmaceutical equipment companies compares the performance of leading companies.
Xinhua Medical released its third quarter report of 2021 on the evening of October 28.
The revenue for the first three quarters of 2021 was 7.
355 billion yuan, a year-on-year increase of 12.
60% , Realized a net profit of 438 million yuan, a year-on-year increase of 105.
59%
.
Performance growth was mainly due to the fact that Xinhua Medical focused on its main business, concentrated on its advantages and focused on the development of medical equipment, pharmaceutical equipment and other business sectors.
Operating income grew steadily, profitability increased, and low-efficiency assets were actively cleared, and investment income increased over the same period
.
Teflon announced on October 11 that the net profit for the first three quarters of 2021 is expected to be between 519 million yuan and 562 million yuan, an increase of 80%-95% year-on-year; the net profit attributable to shareholders of listed companies is 558 million yuan, an increase from the same period last year 93.
69%
.
The company attributed its growth in performance to: the company’s business segments have gradually shown results in new products and new markets over the years, and products in many fields, such as injections, solid preparations, biological macromolecules, and cell equipment, have grown steadily
.
Chutian Technology's 2021 third quarter report disclosed on October 12 showed that the company's main operating income was 3.
682 billion yuan, an increase of 67.
24% year-on-year; the net profit attributable to the parent was 401 million yuan, an increase of 723.
53% year-on-year
.
The company stated that the main reason for the revenue growth was a 98% increase in new orders over the same period in 2020
.
Huasheng Co.
, Ltd.
released its third quarter report on October 25
.
The company's operating income in the first three quarters was 636 million yuan, a year-on-year decrease of 4.
35%; the net profit attributable to the parent was -27.
5864 million yuan, a year-on-year decrease of 186.
87%
.
On the evening of October 28, Tailin Biotechnology released its third quarter report for 2021, stating that the company’s main operating income was 182 million yuan, a year-on-year increase of 36.
18%; net profit attributable to the parent was 42.
375 million yuan, a year-on-year increase of 29.
61%.
Canaan Technology disclosed on October 27, 2021.
In the quarterly report, the company achieved operating income of 752 million yuan in the first three quarters, a year-on-year increase of 24.
50%, and realized a net profit of 57.
68 million yuan attributable to shareholders of listed companies, a year-on-year increase of 10.
63%
.
On the whole, in the first three quarters of 2021, most of the listed pharmaceutical machinery companies have outstanding performance transcripts.
Among them, the leading companies represented by Chutian and Dongfulong have performed outstandingly, and their net profits have increased significantly
.
From the perspective of the entire industry, in 2022, in the domestic market, with the rapid development of the biopharmaceutical industry, the growth of fixed asset investment by pharmaceutical companies, and the trend of import substitution, pharmaceutical companies will have good opportunities; in the international market , Competent domestic pharmaceutical machinery companies are accelerating the introduction of products to overseas markets, accelerating the deployment of international business, and obtaining new growth points
.
Core competitiveness competition R&D investment, talents It is worth mentioning that R&D investment is one of the core competitiveness of pharmaceutical machinery companies in an invincible position in the future market
.
Judging from the R&D situation of the above-mentioned companies, Chutian Technology has made great efforts in R&D
.
Among them, Chutian Technology's R&D investment accounted for a high proportion of revenue every year at about 10%.
The company's R&D investment in the first three quarters of 2021 reached more than 300 million, an increase of more than 60% year-on-year
.
With the continuous high R&D investment, Chutian Technology's innovation results continue to appear.
Since 2021, the company has successfully launched a number of new products.
Among them, Chutian Technology recently released wave-type bioreactors and fully automated microcarriers.
Nearly 20 innovative and upgraded products such as suspension culture bioreactors, basket bioreactors, and disposable mixing and mixing systems
.
In addition, Tofflon’s pharmaceutical equipment products range from API equipment (chemical drug synthesis, traditional Chinese medicine extraction, biological raw liquid) to preparation equipment (injection, oral solid preparation).
Since 2013, the company has basically maintained the proportion of R&D investment in operating income.
At around 7%, and the investment is constantly increasing
.
In the first three quarters of this year, Tofflon’s R&D expenses have exceeded the full-year R&D expenses of 156 million yuan in 2020, an increase of 74.
81% over the same period of the previous year, reaching 166 million yuan
.
With continuous R&D investment, the company's new products and new markets have gradually shown results, and products in many fields, such as injections, solid preparations, biological macromolecules, and cell equipment, have grown steadily
.
The key to corporate competition in the 21st century is talent competition, and talent is also the core competitiveness of pharmaceutical machinery companies
.
Among them, Chutian Technology is a talent technology-oriented enterprise.
Data shows that the number of R&D personnel in Chutian Technology has increased from 428 in 2019 to 1,121 in 2020, with R&D personnel accounting for 36.
94%
.
Up to now, Chutian Technology has more than 1,500 R&D engineers at the Central Research Institute of Technology
.
In order to promote the core competitiveness and long-term development of the company, on December 11, Chutian Technology also announced plans to implement employee equity incentives.
A total of 556 incentive objects were awarded for the first time.
The directors, senior managers, middle managers, core technical personnel and business backbones of the company
.
Conclusion From the perspective of the industry, medicine is a rigid demand.
With the accelerated upgrading of the pharmaceutical industry, there are great opportunities for the pharmaceutical equipment industry
.
However, in the long run, domestic pharmaceutical machinery companies still need to work harder on core competitiveness, including strengthening R&D investment, and cultivating high-level talents that are suitable for the development of the pharmaceutical machinery industry, etc.
, in order to have more competitors in the future market.
Opportunity
.
.
So, in 2021, how about the performance of listed pharmaceutical equipment companies? At present, the listed companies in the domestic pharmaceutical equipment industry mainly include Xinhua Medical, Tofflon, Chutian Technology, Huasheng, Tailin Bio, Canaan Technology, etc.
Let's take a look at their performance
.
Pharmaceutical equipment (picture source: Pharmaceutical Network) The performance of pharmaceutical equipment companies compares the performance of leading companies.
Xinhua Medical released its third quarter report of 2021 on the evening of October 28.
The revenue for the first three quarters of 2021 was 7.
355 billion yuan, a year-on-year increase of 12.
60% , Realized a net profit of 438 million yuan, a year-on-year increase of 105.
59%
.
Performance growth was mainly due to the fact that Xinhua Medical focused on its main business, concentrated on its advantages and focused on the development of medical equipment, pharmaceutical equipment and other business sectors.
Operating income grew steadily, profitability increased, and low-efficiency assets were actively cleared, and investment income increased over the same period
.
Teflon announced on October 11 that the net profit for the first three quarters of 2021 is expected to be between 519 million yuan and 562 million yuan, an increase of 80%-95% year-on-year; the net profit attributable to shareholders of listed companies is 558 million yuan, an increase from the same period last year 93.
69%
.
The company attributed its growth in performance to: the company’s business segments have gradually shown results in new products and new markets over the years, and products in many fields, such as injections, solid preparations, biological macromolecules, and cell equipment, have grown steadily
.
Chutian Technology's 2021 third quarter report disclosed on October 12 showed that the company's main operating income was 3.
682 billion yuan, an increase of 67.
24% year-on-year; the net profit attributable to the parent was 401 million yuan, an increase of 723.
53% year-on-year
.
The company stated that the main reason for the revenue growth was a 98% increase in new orders over the same period in 2020
.
Huasheng Co.
, Ltd.
released its third quarter report on October 25
.
The company's operating income in the first three quarters was 636 million yuan, a year-on-year decrease of 4.
35%; the net profit attributable to the parent was -27.
5864 million yuan, a year-on-year decrease of 186.
87%
.
On the evening of October 28, Tailin Biotechnology released its third quarter report for 2021, stating that the company’s main operating income was 182 million yuan, a year-on-year increase of 36.
18%; net profit attributable to the parent was 42.
375 million yuan, a year-on-year increase of 29.
61%.
Canaan Technology disclosed on October 27, 2021.
In the quarterly report, the company achieved operating income of 752 million yuan in the first three quarters, a year-on-year increase of 24.
50%, and realized a net profit of 57.
68 million yuan attributable to shareholders of listed companies, a year-on-year increase of 10.
63%
.
On the whole, in the first three quarters of 2021, most of the listed pharmaceutical machinery companies have outstanding performance transcripts.
Among them, the leading companies represented by Chutian and Dongfulong have performed outstandingly, and their net profits have increased significantly
.
From the perspective of the entire industry, in 2022, in the domestic market, with the rapid development of the biopharmaceutical industry, the growth of fixed asset investment by pharmaceutical companies, and the trend of import substitution, pharmaceutical companies will have good opportunities; in the international market , Competent domestic pharmaceutical machinery companies are accelerating the introduction of products to overseas markets, accelerating the deployment of international business, and obtaining new growth points
.
Core competitiveness competition R&D investment, talents It is worth mentioning that R&D investment is one of the core competitiveness of pharmaceutical machinery companies in an invincible position in the future market
.
Judging from the R&D situation of the above-mentioned companies, Chutian Technology has made great efforts in R&D
.
Among them, Chutian Technology's R&D investment accounted for a high proportion of revenue every year at about 10%.
The company's R&D investment in the first three quarters of 2021 reached more than 300 million, an increase of more than 60% year-on-year
.
With the continuous high R&D investment, Chutian Technology's innovation results continue to appear.
Since 2021, the company has successfully launched a number of new products.
Among them, Chutian Technology recently released wave-type bioreactors and fully automated microcarriers.
Nearly 20 innovative and upgraded products such as suspension culture bioreactors, basket bioreactors, and disposable mixing and mixing systems
.
In addition, Tofflon’s pharmaceutical equipment products range from API equipment (chemical drug synthesis, traditional Chinese medicine extraction, biological raw liquid) to preparation equipment (injection, oral solid preparation).
Since 2013, the company has basically maintained the proportion of R&D investment in operating income.
At around 7%, and the investment is constantly increasing
.
In the first three quarters of this year, Tofflon’s R&D expenses have exceeded the full-year R&D expenses of 156 million yuan in 2020, an increase of 74.
81% over the same period of the previous year, reaching 166 million yuan
.
With continuous R&D investment, the company's new products and new markets have gradually shown results, and products in many fields, such as injections, solid preparations, biological macromolecules, and cell equipment, have grown steadily
.
The key to corporate competition in the 21st century is talent competition, and talent is also the core competitiveness of pharmaceutical machinery companies
.
Among them, Chutian Technology is a talent technology-oriented enterprise.
Data shows that the number of R&D personnel in Chutian Technology has increased from 428 in 2019 to 1,121 in 2020, with R&D personnel accounting for 36.
94%
.
Up to now, Chutian Technology has more than 1,500 R&D engineers at the Central Research Institute of Technology
.
In order to promote the core competitiveness and long-term development of the company, on December 11, Chutian Technology also announced plans to implement employee equity incentives.
A total of 556 incentive objects were awarded for the first time.
The directors, senior managers, middle managers, core technical personnel and business backbones of the company
.
Conclusion From the perspective of the industry, medicine is a rigid demand.
With the accelerated upgrading of the pharmaceutical industry, there are great opportunities for the pharmaceutical equipment industry
.
However, in the long run, domestic pharmaceutical machinery companies still need to work harder on core competitiveness, including strengthening R&D investment, and cultivating high-level talents that are suitable for the development of the pharmaceutical machinery industry, etc.
, in order to have more competitors in the future market.
Opportunity
.
